Home > Boards > US Listed > Biotechs > Rapture Therapeutics Inc. (RAPT)

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
crudeoil24 Member Profile
Member Level 
Followed By 705
Posts 47,353
Boards Moderated 4
Alias Born 12/12/04
160x600 placeholder
RAPT Therapeutics to Present RPT193 Phase 1b Data at 30th European Academy of Dermatology and Venereology Congress GlobeNewswire Inc. - 9/20/2021 8:00:00 AM
RAPT Therapeutics to Present at the 2021 Cantor Virtual Healthcare Conference GlobeNewswire Inc. - 9/20/2021 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/13/2021 1:30:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/9/2021 7:36:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/3/2021 4:11:08 PM
RAPT Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire Inc. - 9/3/2021 8:00:00 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 8/30/2021 5:22:03 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/17/2021 7:24:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/12/2021 5:27:47 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/11/2021 8:17:13 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/11/2021 8:07:47 AM
RAPT Therapeutics Reports Second Quarter 2021 Financial Results GlobeNewswire Inc. - 8/11/2021 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/9/2021 1:28:56 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/6/2021 1:23:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/26/2021 3:59:37 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/16/2021 1:01:20 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/13/2021 2:35:48 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2021 12:50:34 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/1/2021 4:32:05 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/21/2021 5:06:51 PM
RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchas... GlobeNewswire Inc. - 6/18/2021 12:24:30 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2021 1:23:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/16/2021 6:53:45 PM
RAPT Therapeutics raises $125M via equity offering Seeking Alpha - 6/16/2021 12:06:18 AM
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire Inc. - 6/15/2021 11:07:25 PM
crudeoil24 Member Level  Friday, 11/08/19 01:16:33 PM
Re: None
Post # of 18 
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It is developing selective small molecules designed to modulate the critical immune responses underlying these diseases. It has discovered and advanced two drug candidates FLX475 and RPT193, which is engaged in targeting C-C motif chemokine receptor 4 (CCR4). Its drug discovery and development engine has identified CCR4 as a drug target that potentially has broad applicability in oncology and inflammatory diseases. Its lead oncology drug candidate FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory Treg cells into tumors. Its RPT193 drug candidate, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells), into allergically-inflamed tissues.

New York Yankees and Duke Basketball
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences